A Multicenter, Open-Label Extension Study of WVE-210201 in Patients Previously Enrolled in WVE-DMDX51-001
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2019
Price : $35 *
At a glance
- Drugs Suvodirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors WaVe life Sciences
- 29 Jul 2019 According to a WaVe life Sciences media release, In June, interim data (N=25, data cut off- June 18, 2019) were reported at the 2019 Parent Project Muscular Dystrophy (PPMD) Annual Conference.
- 29 Jul 2019 According to a WaVe life Sciences media release, data from an interim analysis are expected in 4Q 2019. This interim analysis will include dystrophin expression from muscle biopsies taken 22 weeks after patients enrolled in the OLE were transitioned to one of the Phase 2/3 doses of suvodirsen, as well as a safety summary.
- 12 Jun 2019 According to a WaVe life Sciences media release, data from interim analysis of this study is used for submission to the U.S. Food and Drug Administration (FDA) for accelerated approval in the United States in the second half of 2020.